Green Planet Bio Engineering Co. Ltd. — Cyborg Score 1/10

Strategic Profile

The company is a pure shell with no revenue and recurring annual losses of $35,842 in 2025, with all activity focused on staying public while seeking a merger or acquisition target. The balance sheet shows no assets and current liabilities of $500,976 owed to a related party that controls approximately 92% of common stock, creating both financing reliance and concentrated control.

Cyborg Score Rationale

GPLB is a dormant shell company with zero revenue, negative cash flow, substantial going concern doubts, and complete operational inactivity. Its survival depends entirely on securing external financing and completing a business combination.

Top Insights

• Shell corporation status with no active business operations or revenue generation as of 2025
• Going concern warning from auditors regarding ability to continue operations
• Concentrated ownership risk: related-party controls ~92% of shares and holds $484,678 in liabilities
• Penny stock trading at $0.04/share with micro-cap market value (~$800k) and minimal liquidity

Recent Developments

• (March 2026) Annual 10-K filing confirms continued shell status with no revenue, $35,842 net loss in 2025, and no committed financing or acquisition targets
• (April 2010) Company divested Elevated Throne to One Bio Corp after previous agritech operations in China
• (March 2012) Global Funds Holdings Corp. became majority stockholder

Open the full interactive Green Planet Bio Engineering Co. Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.